Introduction
============

Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymomas of the gastrointestinal tract with a smooth muscle origin. The application of immunohistochemistry to the study of GISTs, provides novel insights into the disorder, revealing the contribution of the interstitial cells of Cajal, the spindle cells of the gut wall ([@b1-ol-0-0-4004]--[@b4-ol-0-0-4004]). The majority of GISTs are located within the stomach (50--70%) or the small intestine (20--30%), with as few as 10% of the tumors developing in the rectum, and only 5% developing in the large intestine, the retroperitoneal space and a variety of other locations (i.e., appendix and pancreas) ([@b5-ol-0-0-4004],[@b6-ol-0-0-4004]). These tumors are even less frequent within the mesentery, omentum and esophagus ([@b7-ol-0-0-4004]).

The age of onset for GIST patients is broad, but the tumors commonly occur at 50--60 years. Precise GIST diagnostics became possible only after the 1998 discovery of the c-kit proto-oncogene and cluster of differentiation (CD)117 protein overexpression in the tumor cells ([@b8-ol-0-0-4004]). The biological nature of these tumors, indispensably link the activity of v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) kinase and platelet-derived growth factor receptor α (*PDGFRA*) in cancer progression ([@b9-ol-0-0-4004]--[@b11-ol-0-0-4004]). Notably, 10--15% of tumor cases are not associated with these genes (designated as *KIT/PDGFRA* wild-type), but rather to different carcinogenesis contributors, such as the succinate dehydrogenase complex and mutations of neurofibromin 1, B-Raf proto-oncogene, serine/threonine kinase or Kirsten rat sarcoma viral oncogene homolog kinase ([@b12-ol-0-0-4004],[@b13-ol-0-0-4004]). This broad genetic heterogeneity of GIST highlights the complexity of the tumor origin, but more importantly, further affects the varied responsiveness of GISTs to treatment with the tyrosine kinase inhibitors ([@b14-ol-0-0-4004]).

Meckel\'s diverticulum (MD) is the most frequent congenital defect of the small intestine and is present in \~2% of the general population. Neoplasms of MD are diagnosed only in 0.5--3.2% of the population carrying this anatomical defect ([@b15-ol-0-0-4004]). To date, GISTs of MD origin have not been investigated thoroughly at the genomic level. However, a few case studies have described the tumor tissue examination, showing positive immunohistochemistry reactions for vimentin and c-kit, therefore indicating the GIST nature ([@b15-ol-0-0-4004]--[@b17-ol-0-0-4004]). A previous epidemiological study on 163 MD cases has indicated that MD is a cancer 'hot-spot', comprising an attractive location for tumor development ([@b18-ol-0-0-4004]). Moreover, when comparing different types of cancer, an apparent preponderance of adenocarcinomas versus malignant carcinoids (2:1 ratio) was observed.

The present study attempted to comprehensively explore and reveal the genetic nature of the rare cancer tissue located in MD and investigate its GIST origin.

Patients and methods
====================

### Patient

A 71-year-old woman reported to the Obstetrics and Gynecology Emergency Room (Clinical Hospital, Poznan, Poland) on December 3, 2011, due to newly occurring postmenopausal bleeding. A biopsy of the endometrium was performed and the material obtained was assessed by the Pathology Laboratory. The results of the histopathological examination indicated endometrioid adenocarcinoma (G1). Following the diagnosis, the patient was admitted to the hospital for further treatment. Subsequent to being admitted to the Surgical Gynecology Clinic of the Gynecological and Obstetrics Clinical Hospital, the patient underwent a gynecological examination and a transvaginal ultrasound. Following a cardiology consultation, the patient qualified for elective surgical treatment. During the surgery, the entire uterus with adnexa was removed, and a solid tumor of \~3 cm in size, which was previously not visible in the ultrasound image, was found in MD. The procedure included a complete resection of the tumor along with the diverticulum and an end to end intestinal anastomosis. Tissue samples were sent for a histopathological examination. No intraoperative examinations were performed. There were no complications in the post-operative period or during recovery following the intestinal anastomosis. The patient was discharged from the hospital on the 7th day after the surgery in a good general condition. The patient was advised to await the histopathological examination results and was informed that a decision concerning any further course of treatment would be made based on these results.

### Genetic examination

Once the treatment was completed, advanced molecular testing was employed in order to identify tumor-specific genome changes. Briefly, the Genome-Wide Human CytoScan HD Array and CytoScan 750K (Affymetrix, Santa Clara, CA, USA) was used to analyze genomic alterations in the tumor sample. Genomic DNA was obtained from formalin-fixed paraffin-embedded (FFPE) sections using conventional processing (deparaffinization, enzymatic treatment and DNA extraction) ([@b19-ol-0-0-4004]). The 250 ng of genomic DNA from the tumor was subjected to microarray examination according to the manufacturer\'s protocols as follows: i) Digestion with the restriction enzyme *Nsp*I; ii) adapter ligation, polymerase chain reaction (PCR) amplification and magnetic bead purification; iii) fragmentation and end-labeling with biotin; iv) washing and staining using a GeneChip® Fluidics Station 450; and v) scanning using an Affymetrix GeneChip Scanner 3000 7G (Affymetrix). Scanned data files were generated using Affymetrix GeneChip Command Console Software, version 1.2, and analyzed with Affymetrix Chromosome Analysis Suite v 2.0.0.195 (Affymetrix). To calculate the copy number of altered regions, the data were normalized to baseline reference intensities using NA 32.3 FFPE v.2 reference model (Affymetrix). The hidden Markov model available within the software package was used to determine the copy number states (CN) and their breakpoints. Thresholds of log~2~ ratio ≥0.58 and ≤1 were used to categorize altered regions as CN variation (CNV) gains (amplifications) and copy number losses (deletions), respectively. To prevent the detection of false-positive CNVs arising due to microarray unspecific signals, only regions that involved at least 50 consecutive probes were considered in the analysis of gains or losses in this study. Amplifications and deletions were analyzed separately. To exclude aberrations representing common normal CNVs, all the identified CNVs were compared with those reported in the Database of Genomic Variants (<http://projects.tcag.ca/variation/>). To identify the genes involved in the CNVs further, the UCSC database (<http://genome.ucsc.edu>) and Ensemble (<http://www.ensembl.org>) were used. Gene annotation and gene overlap were determined using the human genome build 19 and NetAffx (<http://www.affymetrix.com>). In addition, the identified alterations were compared with COSMIC database (<http://cancer.sanger.ac.uk>) ([@b20-ol-0-0-4004]) to look for overlap with up-to-date, known genomic cancer regions and single cancer genes. The algorithm for the detection of copy number aberrations in tumor cell mixtures (mosaicism and clonality) considers the comprehensive analysis of adjacent single copy deletions and gains segments. The algorithm is designed to be most accurate when the normal/expected CN is diploid and targets the detection of changes in regions of \~5 Mb or more in size and variation with a minimum of 500 markers (being typical for segments of 5,000 markers or more). This approach considers only a discrete number of mosaicism levels, which are set at 30, 50 and 70%. The range of log ratios is broken into a series of bands according to the detection level (≥30, ≥50% or 70--100% bands) and log ratios within each band denote a specific copy number change event. This tool is most efficient in detecting mosaicism between 30--70% of cells and for copy numbers between 1 and 3. Selected regions were validated in the present study using quantitative PCR (2^−ΔΔCq^; *KIT* gene).

Results
=======

### Clinical findings

The results of the histopathological examination indicated endometrioid adenocarcinoma (G1) and a uterine leiomyoma; GIST, T2 (immunophenotype: CD117^+^, CD34^+^ and vimentin^+^). Laboratory tests, a gynecological examination and transvaginal ultrasound were performed during the next hospital stay. No indications for chemotherapy were identified, the radical nature of the surgery was confirmed, as well as the complete removal of the lesion. After a single day of in-patient treatment, the patient was discharged in a good general condition and was recommended to undergo whole-body positron emission tomography-computed tomography. The scan was performed 12 months after the last hospitalization. No pathological tracer uptake areas were identified. At present, the patient is under the care of the Oncology Outpatient Clinic. No episodes of recurrence had been identified at the time of preparing the manuscript for this case study.

### Genomic studies

The strategy for the reliable detection of chromosomal rearrangements assumes usage of the CytoScan 750K chip in the first step. This investigation resulted in detection of \~62 genomic imbalances that were not filtered out and passed the genomic criteria (\>400 kb; 50 markers). To confirm abnormalities and fine mapping of the borders for genomic segments, a high-resolution chip Cytoscan HD (2.7 million probes and high coverage of 522 cancer genes) was applied. The unbiased density of probes on the chip enabled improvements to the accuracy and confidence of detected regions. A total of 45 previously detected regions were confirmed, and 17 other segments were disregarded as false-positives (signal noise, more rigorous filtering criteria compared with CytoScan 750K chip and usage of FFPE reference model for Cytoscan HD that is far more accurate). In total, the cancer tissue revealed alterations on 6 chromosomes (chromosomes 7, 8, 10, 12, 13 and 19) and 4 entire chromosome aneuploidies (chromosomes 5, 15, 22 and X). A dedicated karyogram illustrating the localization of each segment is shown in [Fig. 1](#f1-ol-0-0-4004){ref-type="fig"}, and an example of mosaic aneuploidy (chromosome 15) is shown in [Fig. 2](#f2-ol-0-0-4004){ref-type="fig"}. The genomic regions where than divided into 4 groups: Low mosaic gains (CN2--3), low mosaic losses (CN2-1), amplifications (CN\>3) and deletions suggestive for loss of heterozygosity (CN\<1). All these data and precise genomic coordinates were incorporated into [Table I](#tI-ol-0-0-4004){ref-type="table"}. Within detected intervals, 4,803 genes were identified. Having high microarray reproducibility, less rigorous criteria were applied to narrow down the abnormality size up to 100 kb (with 50 markers unchanged) to evaluate smaller rearrangements, expanding the genomic area to 442 segments. A focus was placed particularly on known cancer genes (522 entities) and associated pathways that contribute to adenocarcinoma in MD. In order to divulge putative genes contributing to MD adenocarcinoma, the regions for COSMIC genes (known also as Census Genes) ([@b21-ol-0-0-4004]--[@b23-ol-0-0-4004]) were assessed and 88 entities were selected, 43 of which were recurrent ([Table II](#tII-ol-0-0-4004){ref-type="table"}). In order to further delineate the putative cancer pathways, gene-interactions were searched for using the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database (<http://www.genome.jp/kegg>) ([@b24-ol-0-0-4004]). In total, 16 KEGG pathways were selected that are associated with the development of different types of cancer or cellular regulation processes ([Table III](#tIII-ol-0-0-4004){ref-type="table"}). Interacting genes were visualized as a network using String version 9.1 (<http://string-db.org>) ([Fig. 3](#f3-ol-0-0-4004){ref-type="fig"}) ([@b25-ol-0-0-4004]).

Discussion
==========

Current studies are aimed at estimating the incidence of GIST cases in the population. Swedish studies have shown that currently, the number of novel GIST cases amounts to 15--16 million/year ([@b26-ol-0-0-4004]). A tumor may develop in any section of the gastrointestinal tract, as well as intraperitoneally and in the retroperitoneal space. The current state of knowledge and statistical data indicate that when a radical surgical excision of the tumor is possible, the 5-year survival rate is 50--60% ([@b27-ol-0-0-4004],[@b28-ol-0-0-4004]). At the same time, literature references indicate that 80% of patients who undergo surgery experience local recurrence within 2 years of the procedure, and that liver metastases additionally appear in 50% of the patients ([@b29-ol-0-0-4004],[@b30-ol-0-0-4004]). In the case discussed in the present study, the patient was treated surgically for reasons other than a GIST. This problem is widely discussed in the literature. Approximately 40% of women with small intestine GISTs undergo surgery due to genital tract tumors (GIST mimicking pelvic disorders). The genetic mapping of major molecular contributors, tyrosine kinases *KIT* and *PDGFRA* (ref. NM_000222 and NM_006206), reveal that they are located very close to each other on chromosome 4 ([@b31-ol-0-0-4004],[@b32-ol-0-0-4004]) and are found to be mutated in up to 90% of GIST cases. For each, a gain of function mutations results in constitutive activation of the oncogenes, but the clinical consequences may differ significantly ([@b33-ol-0-0-4004],[@b34-ol-0-0-4004]). The biological consequences related to abnormal hyperactivity of both proteins observed in cancer cells for each gene implies the occurrence of a variety of possible mechanisms, including point mutations and bigger genomic instabilities (whole gene amplifications or gene fusions). Hence, the comprehensive molecular portrait of GIST cancers is now emerging. This is possibly due to usage of high-throughput genomic approaches that provide valuable data referring to the involvement of a single gene, but also characterizing entire pathways on various stages of GIST carcinogenesis ([@b35-ol-0-0-4004]--[@b37-ol-0-0-4004]). To date, high-resolution mapping has been conducted only by two groups ([@b36-ol-0-0-4004],[@b38-ol-0-0-4004]), with reference to typical GIST occurrences. Specific chromosomal rearrangements are solid and a consistent finding accompanying KIT and PDGFRA alterations. Losses of chromosomes 1, 3, 13, 14, 15 and 22, whereas gains of chromosomes 4 and 5 may represent clinical utility and prognostic relevance. In the present case, a 15q loss was identified, which is regarded as an aggressive course for a GIST. The loss of 1p was also noted, which is typical for the small intestine localization of tumors, and the absence of a copy number alteration in the *RB1* locus, which is known as a strong clinical predictor ([@b39-ol-0-0-4004]). Application of a high-resolution microarray allows the identification of CN changes at a single gene level (for constitutional disorders, even single exon rearrangements). In the present study, *KIT* gene amplification was detected on chromosome 4, spanning only 163 kb and comprising the entire genomic sequence of this gene. Unexpectedly, the closely located PDGFRA gene (400 kb away) was not altered ([Fig. 4](#f4-ol-0-0-4004){ref-type="fig"}). This finding is reminiscent and indicative of the principal role of KIT in triggering oncogenesis in this case. However, an activating point mutation in another gene cannot be excluded. Alteration of two prominent interacting proteins, PDGFRB and PIK3R1 ([@b40-ol-0-0-4004]), was also found. Phosphorylation of phosphatidylinositol 3-kinase (PIK3R1) by KIT leads to the activation of the v-akt murine thymoma viral oncogene homolog 1 signaling pathway. Activated KIT also transmits signals via growth factor receptor-bound protein 2 and activation of RAS, Raf-1 proto-oncogene, serine/threonine kinase and the mitogen-activated protein kinases (MAPKs) MAPK1/ERK2 and/or MAPK3/ERK1.

In conclusion, by employing a high-resolution microarray, the present study performed a comprehensive genomic analysis on genes contributing to GISTs, in the rare location of MD. A principal role of the *KIT* gene was confirmed in cancer initiation, which was demonstrated by detailed histopathological and molecular investigations. The detected chromosomal gains and losses were consistent with the findings of a GIST and confirm previous studies. Possible chemokine and cytokine-related signaling pathways (PIK3R1, BRAF, MAP2K1, PDGFRB and PDGFB) that may reasonably contribute to cancer progression with GIST characteristics were also indicated.
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![An example of microarray analysis of chromosome 15. Log~2~ ratio and copy number state in examined formalin-fixed paraffin-embedded (FFPE) tumor tissue are shown.](ol-11-02-1007-g01){#f2-ol-0-0-4004}

![String visualization of the network interaction of all 87 selected cancer proteins. Proteins reported to be altered and contributing to Kyoto Encyclopedia of Genes and Genomes 'Pathways in cancer' (hsa05200; [Table III](#tIII-ol-0-0-4004){ref-type="table"}) are indicated in dark gray (12 genes).](ol-11-02-1007-g02){#f3-ol-0-0-4004}

![A high-resolution examination of 4q12 region presenting amplification of the *KIT* gene and no copy number state alteration of the *PDGFRA* gene. *PDGFRA*, platelet-derived growth factor receptor α; FFPE, formalin-fixed paraffin-embedded.](ol-11-02-1007-g03){#f4-ol-0-0-4004}

###### 

Genomic alterations (\>400 kb in size) found in examined tumor. Any overlapping cancer genes (COSMIC) are additionally listed using gene ID.

  Case   CN     Type   Chromosome   Cytoband start   Start       End         Size, kbp   Gene count, total   Census gene count   Gene name (s)
  ------ ------ ------ ------------ ---------------- ----------- ----------- ----------- ------------------- ------------------- ---------------------------------------------------------------------------------------
    1    2.29   Gain     5          p15.33           113576      10070760    9957.184      63                  1                 TERT
    2    2.25   Gain     5          p15.2            12452650    21850508    9397.858      19                                    
    3    2.33   Gain     5          p14.1            27490784    85587655    58096.871   274                   4                 IL7R, IL6ST, PIK3R1, LIFR
    4    \>3    Gain     5          p13.3            33484586    33897522    412.936         1                                   
    5    \>3    Gain     5          q11.2            56710608    57133644    423.036         1                                   
    6    2.25   Gain     5          q14.3            87860680    98769659    10908.979     42                                    
    7    2.33   Gain     5          q21.1            99756189    160909509   61153.32    438                 5                   CD74, ITK, EBF1, APC, PDGFRB
    8    \>3    Gain     5          q23.3            127572667   128144311   571.644         1                                   
    9    2.32   Gain     5          q34              161866188   180719789   18853.601   159                 4                   NPM1, RANBP17, NSD1, TLX3
  10     2.23   Gain     7          p22.3            43360       6483365     6440.005      75                3                   pMS2, CARD11, RAC1
  11     2.21   Gain     7          p15.2            26483627    30210591    3726.964      42                4                   HOXA11, HOXA9, HOXA13, JAZF1
  12     2.29   Gain     7          p14.1            37893184    45800150    7906.966      70                                    
  13     2.22   Gain     7          q11.21           66150834    71291670    5140.836      14                                    SBDS
  14     2.22   Gain     7          q21.3            94402911    98900790    4497.879      32                1                   TRRAP
  15     2.25   Gain     7          q31.33           126728205   141381467   14653       127                 4                   KIAA1549, CREB3L2, SMO, BRAF
  16     2.22   Gain     8          p23.3            158048      35996434    35838.386   255                                     pCM1, WRN
  17     2.24   Gain     8          p12              36003284    48320037    12316.753     66                3                   HOOK3, FGFR1, WHSC1L1
  18     2.22   Gain     8          q22.1            93943335    99747954    5804.619      46                                    
  19     2.22   Gain     8          q24.23           139395919   145287179   5891.26       77                                    
  20     \>3    Gain   10           q11.22           46976673    48174779    1198.106      17                                    
  21     2.26   Gain   12           p13.33           173786      15842149    15668.363   244                 4                   ZNF384, KDM5A, CCND2, ETV6,
  22     2.22   Gain   12           q13.11           49073505    57666097    8592.592    253                 5                   HOXC11, KMT2D, HOXC13, NACA, ATF1
  23     2.22   Gain   12           q23.3            107607681   112259343   4651.662      58                2                   SH2B3, ALDH2,
  24     2.22   Gain   12           q24.21           114772266   119550739   4778.473      23                                    
  25     2.24   Gain   13           q12.3            31303510    38510652    7207.142      43                1                   BRCA2
  26     1.47   Loss   15           q11.2            22770421    102429112   79658.691   799                 8                   BLM, PML, NTRK3, TCF12, IDH2, CRTC3, BUB1B, MAP2K1
  27     \<1    Loss   15           q21.1            47407284    47903647    496.363         1                                   
  28     \<1    Loss   15           q21.3            53994492    54476263    481.771         2                                   
  29     \<1    Loss   15           q21.3            54866217    55494071    627.854         2                                   
  30     \<1    Loss   15           q23              68667321    69080873    413.552         3                                   
  31     \<1    Loss   15           q23              70688921    71128704    439.783         2                                   
  32     \<1    Loss   15           q26.1            89819011    90281381      462.37      11                                    
  33     \<1    Loss   15           q26.2            94991252    95497814    506.562         1                                   
  34     \<1    Loss   15           q26.2            97288627    98205766    917.139         1                                   
  35     2.25   Gain   19           q13.43           56862882    58956888    2094.006      75                                    
                                                                                                                                 
  Case   CN     Type   Chromosome   Cytoband start   Start       End         Size, kbp   Gene count, total   Census gene count   \% of overlap map item covered by segment
                                                                                                                                 
  36     1.7    Loss   22           q11.1            16888899    50902452    34013.553   525                 11                  CHEK2, MKL1, CLTCL1, NF2, EWSR1, MN1, SMARCB1, PDGFB, EP300, MYH9, BCR
  37     2.32   Gain     X          p22.33           168546      32908751    32740.205   165                   3                 CRLF2, ZRSR2, P2RY8,
  38     2.46   Gain     X          p21.1            32388483    113724212   81335.729   488                 14                  SSX1, MSN, KDM5C, KDM6A, ATRX, BCOR, SSX2, NONO, GATA1, TFE3, SSX4, AMER1, WAS, MED12
  39     \>3    Gain     X          q11.2            64280772    64692636    411.864         0                                   
  40     \>3    Gain     X          q13.2            71859817    72307913    448.096         8                                   
  41     \>3    Gain     X          q21.31           88759463    89169371    409.908         0                                   
  42     \>3    Gain     X          q21.32           91923926    92392650    468.724         0                                   
  43     \>3    Gain     X          q21.33           95094694    95611952    517.258         1                                   
  44     \>3    Gain     X          q22.3            108029759   108614975   585.216         0                                   
  45     2.38   Gain     X          q23              114896478   155233731   40337.253   345                     8               ATP2B3, PHF6, STAG2, SEPT6, GPC3, RPL10, ELF4, MTCP1

CN, copy number state.

###### 

COSMIC database reporting genes to be mutated in gastrointestinal tract (site indeterminate and various tumor types) and small intestine adenocarcinoma.^[a](#tfn2-ol-0-0-4004){ref-type="table-fn"}^

  Case      Gene           Mutated samples   Sample tested
  --------- -------------- ----------------- ---------------
    1       *NRAS*         79                502
    2       *HRAS*         31                495
    **3**   ***TERT***     **28**              **97**
    4       *KRAS*         19                490
    5       *PIK3CA*       14                194
    6       *PTEN*         11                150
    **7**   ***BRAF***       **8**           **595**
    8       *TSHR*           8                 50
    9       *IDH1*           6                 53
  10        *CDKN2A*         4                 28
  11        *MET*            2                 41
  12        *TP53*           2                 20
  13        *GNAS*           2                 73
  14        *PAX8*           0               142
  15        *EGFR*           0               101
  16        *CCDC6*          0                 80
  17        *PDGFRA*         0                 64
  **18**    ***KIT***        **0**             **64**
  19        *NCOA*           0                 55
  20        *GNA11*          0                 46
  21        *GNAQ*           0                 42
  **22**    ***PIK3R1***     **0**             **34**
  **23**    ***IDH2***       **0**             **32**
  24        *AKT1*           0                 23
  25        *ALK*            0                 22
  26        *RET*            0                 21
  27        *PRKAR1A*        0                 16
  28        *MEN1*           0                 15
  **29**    ***APC***        **0**             **15**
  **30**    ***MAP2K1***     **0**             **13**
  31        *STRN*           0                 11
  32        *VHL*            0                 10
  **33**    ***NPM1***       **0**             **10**
  34        *CDH1*           0                   8
  35        *TFG*            0                   6
  36        *TPR*            0                   6
  37        *JAK2*           0                   6
  38        *CTNNB1*         0                   4
  39        *SF3B1*          0                   4
  **40**    ***KDM6A***      **0**               **4**
  41        *SMAD4*          0                   4
  42        *PTPN11*         0                   3
  43        *TPM3*           0                   2

Genes contributing to the case and found within altered regions are in bold.

###### 

Kyoto Encyclopedia of Genes and Genomes pathway and statistical analysis for involvement of selected cancer genes present in altered genomic regions and their contribution to different cancer types or cellular control.

  Case   Gene ontology ID   Term                                     P-value         No. of genes   Genes
  ------ ------------------ ---------------------------------------- --------------- -------------- ------------------------------------------------------------------------------------------------------
    1    hsa05200           Pathways in cancer                         1.29×10^−6^   12             *BCR*, *APC*, *SMO*, *PDGFRB*, *PDGFB*, *EP300*, *BRAF*, *MAP2K1*, *PIK3R1*, *BRCA2*, *FGFR1*, *PML*
    2    hsa05215           Prostate cancer                            1.27×10^−7^     8            *CREB3L2*, *PIK3R1*, *PDGFRB*, *PDGFB*, *EP300*, *FGFR1*, *BRAF*, *MAP2K1*
    3    hsa05218           Melanoma                                 7.8×10^−6^        6            *PIK3R1*, *PDGFRB*, *PDGFB*, *FGFR1*, *BRAF*, *MAP2K1*
    4    hsa05214           Glioma                                   6.4×10^−5^        5            *PIK3R1*, *PDGFRB*, *PDGFB*, *BRAF*, *MAP2K1*
    5    hsa04630           Jak-STAT signaling pathway                 8.73×10^−5^     7            *PIK3R1*, *IL7R*, *CCND2*, *CRLF2*, *IL6ST*, *EP300*, *LIFR*
    6    hsa05211           Renal cell carcinoma                       1.08×10^−4^     5            *PIK3R1*, *PDGFB*, *EP300*, *BRAF*, *MAP2K1*
    7    hsa05213           Endometrial cancer                         4.39×10^−4^     4            *APC*, *PIK3R1*, *BRAF*, *MAP2K1*
    8    hsa05221           Acute myeloid leukemia                     5.87×10^−4^     4            *PIK3R*, *PML*, *BRAF*, *MAP2K1*
    9    hsa05210           Colorectal cancer                          6.73×10^−4^     4            *APC*, *PIK3R1*, *BRAF*, *MAP2K1*
  10     hsa05212           Pancreatic cancer                          1.04×10^−3^     4            *PIK3R1*, *BRCA2*, *BRAF*, *MAP2K1*
  11     hsa05220           Chronic myeloid leukemia                   1.38×10^−3^     4            PIK3R1, *BRAF*, *MAP2K1*, *BCR*
  12     hsa04110           Cell cycle                                 1.51×10^−3^     5            *CCND2*, *CHEK2*, *STAG2*, *EP300*, *BUB1B*
  13     hsa04510           Focal adhesion                             2.43×10^−3^     6            *PDGFRB*, *PDGFB*, *BRAF*, *MAP2K1*, *PIK3R1*, *CCND2*
  14     hsa05223           Non-small cell lung cancer                 5.86×10^−3^     3            *PIK3R1*, *BRAF*, *MAP2K1*
  15     hsa04062           Chemokine signaling pathway                8.99×10^−3^     5            *PIK3R1*, *WAS*, *BRAF*, *MAP2K1*, *ITK*
  16     hsa04060           Cytokine-cytokine receptor interaction     9.63×10^−3^     6            *CRLF2*, *IL6ST*, *PDGFRB*, *PDGFB*, *LIFR*, *IL7R*

JAK/STAT, Janus kinase/signal transducer and activator of transcription.

[^1]: Contributed equally
